ReviewInternational journal of molecular sciences2025
The Role of Calprotectin in the Diagnosis and Treatment of Inflammatory Bowel Disease.
Review in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed.
- Assessment of faecal calprotectin in neonatal calf diarrhoea using a human ELISA kit: Associations with faecal score and serum biochemical markers.Veterinary record open · 2026Article
- The Childhood Liver Disease Research Network's prospective characterization of pediatric primary sclerosing cholangitis.Hepatology communications · 2026Observational
- The Effects of Vitamin DAnimals : an open access journal from MDPI · 2026Article
- Elevated Serum Soluble CD137 in Inflammatory Bowel Disease and Primary Sclerosing Cholangitis Highlights a Shared Immunoregulatory Signature.Biomedicines · 2026Article
- Comparative Evaluation of Serum Hepcidin and Fecal Calprotectin for Disease Activity Assessment in Inflammatory Bowel Disease.The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology · 2026Article
- Evaluating the correlation between fecal and serum calprotectin in inflammatory bowel disease.Scientific reports · 2026Observational
- Biosensor-Based Detection of Calprotectin and Lactoferrin as Neutrophil-Derived Markers of Inflammatory Bowel Diseases: From Molecular Pathophysiology to Point-of-Care Platforms.International journal of molecular sciences · 2026Review
- Calprotectin as a Potential Biomarker for Inflammation in Lung Cancer Patients.Diagnostics (Basel, Switzerland) · 2026Article
- Article
- The Roles of Four Neutrophil-Derived Proteins as Non-Invasive Biomarkers in the Assessment of Inflammatory Bowel Disease.Journal of inflammation research · 2026Review
- Immune-related mechanisms of fecal microbiota transplantation in the intestinal microenvironment as a potential intervention for autism spectrum disorder patients.Frontiers in pharmacology · 2026Review
- Intermittent fasting and immune aging: implications for immunosenescence, inflammaging, neuroinflammation, and frailty.Frontiers in nutrition · 2026Review
- Efficacy of 2,4-Dinitrobenzenesulfonic Acid (DNBS) in the Maintenance of a Model of Inflammatory Bowel Disease in Pigs (International journal of molecular sciences · 2025Article
- Inflammatory Bowel Disease (IBD): Clinical Diagnosis and Treatment.Journal of clinical medicine · 2025Article
- Serum C-Reactive Protein as a Potential Indicator for Screening Fecal Calprotectin in Patients With Moderate-to-Severe Hidradenitis Suppurativa: A Cross-Sectional Cohort Study.International journal of dermatology · 2025Article
- Information Needs of Patients with Inflammatory Bowel Disease in the Digital Era: A 20-Year Longitudinal Study.Journal of clinical medicine · 2025Article
- Fecal Arachidonic Acid: A Potential Biomarker for Inflammatory Bowel Disease Severity.International journal of molecular sciences · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The management of inflammatory bowel disease (IBD), which is characterized by immunodeficiency, has attracted increasing attention, highlighting the necessity for more precise and streamlined diagnostic approaches in clinics. Calprotectin, an immune cell-derived protein with inherent anti-inflammatory and antimicrobial properties, plays a pivotal role in immune regulation and intestinal homeostasis. Its expression levels are intricately linked to IBD activity, enabling differentiation between inflammatory and non-inflammatory states while predicting recurrence risks. As a non-invasive biomarker, fecal calprotectin (FC) and serum calprotectin (SC) analysis offers high reproducibility and clinical utility, facilitating both IBD diagnosis and real-time disease monitoring. Beyond its diagnostic specificity in distinguishing IBD from other gastrointestinal disorders, calprotectin also emerges as a promising therapeutic target, due to its dual role in modulating inflammatory pathways and interacting with the gut microbiota. With collaborative advancements in standardized detection protocols and innovative research methodologies, it is anticipated that calprotectin-based strategies will be integrated into mainstream clinical practice for IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.